ERS Genomics Licenses CRISPR-Cas9 Patent And Technology To Cellular Engineering Technologies – Food, Drugs, Healthcare, Life Sciences

Recently, Dublin, Ireland-based biotechnology company, ERS
Genomics Limited (“ERS”), has signed a
nonexclusive license agreement with Iowa-based Cellular
Engineering Technologies (“CET”) to grant access to its
CRISPR-Cas9 patent portfolio. The financial terms of the
agreement were not disclosed.

ERS was formed to provide broad access to the foundational
CRISPR/Cas9 intellectual property for use as a research platform.
ERS holds an exclusive worldwide license on these technologies from
ERS co-founder, inventor, and Nobel laureate, Dr. Emmanuelle
Charpentier.

Cellular Engineering Technologies (CET) is a biotechnology
company in personalized and regenerative medicine.  Our
mission is to decrease the cost and failure rate of drug
development and create therapeutic modalities in regenerative
medicine.  CET specializes in cell manufacturing and contract
research services directed towards biopharmaceutical market
segments that interface with stem cell technology. CET has over a
decade of being in business with core competencies in specialized
tissue culture media formulation and cell manufacturing along with
research services that use human non-embryonic sources and
non-controversial cells for bioprocessing.

The CRISPR/Cas9 is a revolutionary technology in which the
molecular complex binds to the genome in living cells at any
desired location. By this method, researchers use CRISPR as a
“molecular word processor” to specifically alter the DNA
sequence at the targeted sites (DNA deletion, insertion, or
replacement), alter the regulation of the target locus, or tag the
locus with markers.

ERS has a portfolio of over 60 granted patents with around 30 in
the US alone. Some of the US patents include:

• 10000772: Methods and compositions for RNA-directed target DNA
  modification and for RNA-directed modulation of transcription




• 10227611: Methods and compositions for RNA-directed target DNA
  modification and for RNA-directed modulation of transcription




• 10301651: Methods and compositions for RNA-directed target DNA
  modification and for RNA-directed modulation of transcription




• 10626419: Methods and compositions for RNA-directed target DNA
  modification and for RNA-directed modulation of transcription

CRISPR, an acronym for Clustered Regularly Interspaced Short
Palindromic Repeats (CRISPR), and this is usually done by the use
of an enzyme called Cas9, there CRISPT-Cas9. CRISPR-Cas9 system has
revolutionized the field of gene editing, facilitating efficient
genome editing by the creation of targeted double-strand breaks of
almost any organism and cell type. CRISPR-Cas9 technology has been
especially useful in gene therapy fields and has also been used for
regulation of endogenous gene expression, epigenome editing,
live-cell labeling of chromosomal loci, edition of single-stranded
RNA, and high-throughput gene screening.

The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.